NANOFS.ST Nanoform Finland Plc

Healthcare Biotechnology Stockholm Exchange
7.53 SEK
Close of Nov 7, 2026
4.15 13.22
Market cap
SEK 646M
P/E
-
P/B
1.66x
ROE
-39.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NANOFS.ST undervalued?

Graham number

The Graham number of Nanoform Finland Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nanoform Finland Plc fundamental analysis

No fundamental analysis for Nanoform Finland Plc yet.

Nanoform Finland Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nanoform Finland Plc

Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosag…

Full company profile